GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keryx Biopharmaceuticals Inc (NAS:KERX) » Definitions » Cyclically Adjusted PB Ratio

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Cyclically Adjusted PB Ratio : (As of May. 05, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Keryx Biopharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Keryx Biopharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Keryx Biopharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keryx Biopharmaceuticals Cyclically Adjusted PB Ratio Chart

Keryx Biopharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Keryx Biopharmaceuticals Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Keryx Biopharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Keryx Biopharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Keryx Biopharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keryx Biopharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Keryx Biopharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Keryx Biopharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Keryx Biopharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2018 is calculated as:

For example, Keryx Biopharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2018 was:

Adj_Book=Book Value per Share/CPI of Sep. 2018 (Change)*Current CPI (Sep. 2018)
=-0.45/106.5067*106.5067
=-0.450

Current CPI (Sep. 2018) = 106.5067.

Keryx Biopharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
200812 -0.033 88.697 -0.040
200903 -0.010 89.744 -0.012
200906 0.315 91.003 0.369
200909 0.626 91.120 0.732
200912 0.568 91.111 0.664
201003 0.502 91.821 0.582
201006 0.463 91.962 0.536
201009 0.453 92.162 0.524
201012 0.378 92.474 0.435
201103 0.283 94.283 0.320
201106 0.674 95.235 0.754
201109 0.548 95.727 0.610
201112 0.437 95.213 0.489
201203 0.317 96.783 0.349
201206 0.299 96.819 0.329
201209 0.231 97.633 0.252
201212 0.146 96.871 0.161
201303 1.026 98.209 1.113
201306 0.896 98.518 0.969
201309 0.715 98.790 0.771
201312 0.549 98.326 0.595
201403 1.583 99.695 1.691
201406 1.355 100.560 1.435
201409 1.073 100.428 1.138
201412 0.793 99.070 0.853
201503 1.627 99.621 1.739
201506 1.399 100.684 1.480
201509 1.151 100.392 1.221
201512 0.827 99.792 0.883
201603 0.467 100.470 0.495
201606 0.565 101.688 0.592
201609 0.208 101.861 0.217
201612 -0.078 101.863 -0.082
201703 -0.209 102.862 -0.216
201706 0.216 103.349 0.223
201709 0.075 104.136 0.077
201712 -0.118 104.011 -0.121
201803 -0.262 105.290 -0.265
201806 -0.342 106.317 -0.343
201809 -0.450 106.507 -0.450

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Keryx Biopharmaceuticals  (NAS:KERX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Keryx Biopharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.
Executives
Scott A Holmes officer: Chief Financial Officer C/O KERYX BIOPHARMACEUTICALS INC 1 MARINA PARK DR., 10TH FLOOR BOSTON MA 02210
Daniel Paul Regan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Jodie Pope Morrison director, officer: Interim CEO C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Mark J Enyedy director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Michael W Rogers director C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Baupost Group Gp, L.l.c. 10 percent owner 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Baupost Group Llc/ma director, 10 percent owner 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
Seth A Klarman 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Greg Madison director, officer: President and CEO ONE MARINA PARK DRIVE LEXINGTON MA 02210
Brian Adams officer: General Counsel and Secretary 750 LEXINGTON AVENUE, NEW YORK NY 10022
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Sak Corp 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Oliviero James F Iii officer: Chief Financial Officer C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022